Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study

Cancer Science

Volumn 107, Issue 2, 2016, Pages 173-180

  Syn, Nicholas Li Xun ^a,b   Wang, Lingzhi ^a,b,c   Wong, Andrea Li Ann ^a   Soe, Mu Yar ^a   Chuah, Benjamin ^a   Chan, Daniel ^a   Tan, Sing Huang ^a   Soo, Ross Andrew ^a,b   Lee, Soo Chin ^a,b   Goh, Boon Cher ^a,b,c   Yong, Wei Peng ^a,b  

^a Singapore   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antineoplastic combined chemotherapy protocols; Biomarkers; Neutropenia; Pharmacokinetics; Taxoids

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; ASIAN; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY; LIVER DYSFUNCTION; MALE; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; MUCOSA INFLAMMATION; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; SEPSIS; AREA UNDER THE CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; LIVER; LIVER DISEASES; MIDDLE AGED; NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; ROC CURVE; TAXOIDS;

EID: 84958941706     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12856     Document Type: Article

References (18)

1. Edwards BK, Noone AM, Mariotto AB et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014; 120: 1290-314.
2. Field KM, Michael M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol 2008 Dec; 9: 1181-90.
3. Tran A, Jullien V, Alexandre J et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006 Jun; 79: 570-80.
4. Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol 2008 Nov; 9: 1092-101.
5. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999 Feb; 36 (2) : 99-114.
6. Minami H, Kawada K, Sasaki Y et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci 2009; 100 (1) : 144-9.
7. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998 Jan; 16 (1) : 187-96.
8. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 Aug; 60: 646-9.
9. Patel H, Egorin MJ, Remick SC et al. Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing. ASCO Meet Abstr 2004 Jul; 22 (Suppl): 6051.
10. Millward MJ, Boyer MJ, Lehnert M et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003 Mar; 14: 449-54.
11. Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose. Cancer Sci 2015 May; 106: 497-504.
12. Goh BC, Lee SC, Wang LZ et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-90.
13. D'Argenio D, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/pharmacodynamic systems analysis software. Biomed Simulations Resour Los Angeles; 1997.
14. Wang LZ, Goh BC, Grigg ME, Lee SC, Khoo YM, Lee HS. A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. Rapid Commun Mass Spectrom 2003 Jan; 17: 1548-52.
15. Minami H, Kawada K, Sasaki Y et al. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Sci 2006; 97: 235-41.
16. Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003 Oct; 74: 364-71.
17. Mauri D, Kamposioras K, Tsali L et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev 2010 Feb; 36: 69-74.
18. Di Maio M, Perrone F, Chiodini P et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007 Apr 25: 1377-82.